Navigation Links
FirstMark Exhibiting and Presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium

SAN DIEGO, June 20, 2012 /PRNewswire-iReach/ -- FirstMark, the diagnostic division of GenWay Biotech, Inc., is pleased to announce that the company will be exhibiting and presenting at the San Diego Academy of Family Physicians 55th Annual Postgraduate Symposium, in San Diego, June 22-24. FirstMark will showcase the groundbreaking research and data that is the foundation for PREvent. PREvent is the first and only multiple biomarker blood test on the market that accurately predicts near term (2-3 years) risk of myocardial infarction (MI) and death for coronary artery disease (CAD) patients. PREvent is an exciting development in cardiovascular patient management, addressing the unmet need to assess the risk of near term MI.

Dr. Sergey Sikora, Sr. Vice President of FirstMark, will present the research and data at the Symposium at 12:00 p.m. – 1:00  p.m., Sunday, June 24th, Paradise Point Resort at Mission Bay, Garden Room. Dr. Sikora is co-creator of a PREvent, along with noted cardiologists and researchers Dr. Arshed Quyyumi at Emory University, and Dr. Stephen Epstein at MedStar Health Research Institute. FirstMark will be exhibiting at the symposium on Friday, June 22nd, and Saturday, June 23rd.

"We look forward to the opportunity to present to the family physicians in attendance at the symposium," said Dr. Sikora. "The symposium focuses on novel technologies that determine patients at risk for particular medical conditions, in order to control or prevent further complications. This event provides a perfect setting for FirstMark to share the remarkable research data and benefits of PREvent. We believe many of the physicians that are in attendance will find PREvent of interest with strong potential for clinical application for their CAD patients."

PREvent provides superior cardiac risk information by identifying the top 5% of CAD at the highest risk of MI with a hazard ratio of 5.5. The data showed an annualized event rate of MI or death for 18.2% of significant CAD patients with all three biomarkers elevated as compared to only 2.45% of significant CAD patients with all biomarkers normal. The multiple biomarker model adds markedly to traditional risk-prediction by significantly improving C-statistics from 0.695 for base model to 0.750, distinguishing high risk from low risk patients.

About FirstMark
FirstMark is a division of GenWay Biotech, Inc. The FirstMark division is focused on the development and commercialization of non-invasive diagnostic and health monitoring tests for unmet clinical needs. Headquarters are located in the heart of San Diego's biotech community in the Sorrento Valley/Mesa area. For additional information please visit

Media Contact: Deborah Moore FirstMark, 858-458-0866 x 113,

News distributed by PR Newswire iReach:



SOURCE FirstMark
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board
2. FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisor Board
3. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
4. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
5. 2012 AAPS National Biotechnology Conference heads to San Diego
6. Harris Lewin elected to National Academy of Sciences
7. Professor known for work with hunter-gatherers elected to American Academy of Arts and Sciences
8. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
9. Family values
10. Discovery of a new family of key mitochondrial proteins for the function and viability of the brain
11. Starting a family does not encourage parents to eat healthier
Post Your Comments:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
Breaking Biology Technology: